Nokota Management LP raised its stake in shares of Allergan plc (NYSE:AGN) by 11.4% in the second quarter, Holdings Channel reports. The institutional investor owned 359,331 shares of the company’s stock after buying an additional 36,700 shares during the quarter. Allergan accounts for about 0.9% of Nokota Management LP’s holdings, making the stock its 24th biggest position. Nokota Management LP’s holdings in Allergan were worth $59,908,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in AGN. Parnassus Investments CA increased its holdings in shares of Allergan by 3.1% in the 2nd quarter. Parnassus Investments CA now owns 1,844,804 shares of the company’s stock worth $307,566,000 after purchasing an additional 55,029 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Allergan by 2.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 3,545,557 shares of the company’s stock worth $591,116,000 after purchasing an additional 99,490 shares in the last quarter. Arbor Wealth Management LLC increased its holdings in shares of Allergan by 92.8% in the 1st quarter. Arbor Wealth Management LLC now owns 13,846 shares of the company’s stock worth $2,137,000 after purchasing an additional 6,663 shares in the last quarter. Toronto Dominion Bank increased its holdings in shares of Allergan by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 517,895 shares of the company’s stock worth $90,451,000 after purchasing an additional 7,683 shares in the last quarter. Finally, HL Financial Services LLC increased its holdings in shares of Allergan by 32.2% in the 2nd quarter. HL Financial Services LLC now owns 601,456 shares of the company’s stock worth $100,275,000 after purchasing an additional 146,645 shares in the last quarter. Institutional investors and hedge funds own 77.37% of the company’s stock.
In related news, Director Joseph H. Boccuzi purchased 900 shares of the business’s stock in a transaction on Thursday, August 30th. The stock was acquired at an average price of $190.59 per share, with a total value of $171,531.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.36% of the company’s stock.
Shares of AGN opened at $191.24 on Thursday. The company has a debt-to-equity ratio of 0.34, a current ratio of 1.00 and a quick ratio of 0.85. Allergan plc has a one year low of $142.81 and a one year high of $237.41. The firm has a market capitalization of $65.07 billion, a P/E ratio of 11.70, a PEG ratio of 1.47 and a beta of 1.21.
Allergan (NYSE:AGN) last released its quarterly earnings results on Thursday, July 26th. The company reported $4.42 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.13 by $0.29. Allergan had a positive return on equity of 8.60% and a negative net margin of 10.29%. The business had revenue of $4.10 billion during the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the previous year, the company posted $4.02 earnings per share. Allergan’s revenue for the quarter was up 2.3% on a year-over-year basis. equities research analysts predict that Allergan plc will post 16.29 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, September 17th. Shareholders of record on Friday, August 17th will be issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.51%. The ex-dividend date of this dividend is Thursday, August 16th. Allergan’s dividend payout ratio is presently 17.61%.
AGN has been the subject of a number of research analyst reports. Zacks Investment Research raised Allergan from a “hold” rating to a “buy” rating and set a $193.00 target price for the company in a report on Tuesday, July 24th. Wells Fargo & Co reissued a “buy” rating on shares of Allergan in a report on Tuesday, June 5th. Cantor Fitzgerald set a $180.00 target price on Allergan and gave the stock a “hold” rating in a report on Thursday, July 26th. Bank of America lifted their target price on Allergan from $209.00 to $213.00 and gave the stock a “buy” rating in a report on Tuesday, June 12th. Finally, TheStreet raised Allergan from a “d+” rating to a “c” rating in a report on Monday, August 20th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $210.10.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women's health, urology, and anti-infective therapeutic categories.
Read More: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.